583 results
REC-CAGEFREE II, NOTION-2, LANDMARK: Three major late-breaking trials presented at EuroPCR 2024
15 May 2024
The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.
Artificial intelligence-powered quantification of coronary physiology and vulnerable plaque: opportunities for novel treatment options
15 May 2024 – From EuroPCR 2024
In this session, uncover new data on Murray-law based quantitative flow ratio (muFR) assessment, providing a comprehensive understanding of PCI outcomes from a single angiographic view, explore the innovative application of artificial intelligence in identifying vulnerable plaque and assessing hemodynamic stenosis significance through the analysis of...
Complex PCI in ACS patient with high bleeding risk: optimise the strategy
15 May 2024 – From EuroPCR 2024
Watch this session for insights into managing acute coronary syndrome patients with multivessel disease, updates on treatment approaches, comparing FULL RESVAC with previous trials like COMPLETE or FIRE, for example, and information on ongoing trials such as FRAMI-AMI 2 and 3. Explore the LIVE case presentation...
Second generation biolimus drug-coated balloon in clinical practice
15 May 2024 – From EuroPCR 2024
Discover the potential applications of the new biolimus-coated balloon in treating de novo large vessel lesions, explore its effectiveness in addressing ISR based on findings from the BIO ASCEND ISR study, and uncover insights into the safety and feasibility of BA9 DCB in treating small vessel,...
Go beyond metal: exploring drug-eluting balloon technology in de-novo coronary lesions
15 May 2024 – From EuroPCR 2024
Through the study of two cases, this session examines the need for stenting bifurcation lesions and the role of DEB technology in avoiding stent-related complications in long diffuse disease. It emphasizes the benefits of SELUTION SLR balloons for de novo lesions, discussing how sustained limus release...
Randomised trials: substudies and extended follow-up - A quick update
15 May 2024 – From EuroPCR 2024
This session provides a quick update on various randomised trials, including substudies and extended follow-up data. It covers insights on bifurcation stenting, the symptom-stratified analysis of ORBITA-2, the impact of completeness of revascularisation on clinical outcomes from REVIVED-BCIS2, cost-effectiveness of CABG vs. PCI from FAME 3,...
The ARC consensus on DCB - evidence-based DCB technology
15 May 2024 – From EuroPCR 2024
In this replay, discover why DCBs are essential in treating de novo CAD, the importance of optimal lesion preparation for long-term success, and how future trials will focus on treatment strategies rather than device comparisons, highlighting the need for further research.
PCI complications: device-related issues, perforations and other unexpected events
15 May 2024 – From EuroPCR 2024
This session focuses on the management of various complications that can occur during percutaneous coronary intervention (PCI), including device-related issues, perforations, and other unexpected events. Attendees will learn from case presentations and discussions on strategies to identify, mitigate, and manage these complications, with a focus on...
Stentless PCI
15 May 2024 – From EuroPCR 2024
This session explores various stentless percutaneous coronary intervention (PCI) strategies, including drug-coated balloon (DCB)-only PCI for chronic total occlusions and de-novo coronary lesions, as well as the use of magnesium resorbable scaffolds. Attendees will learn about the rationale, techniques, and outcomes of these "leave nothing behind"...
An image is worth a 1,000 words
15 May 2024 – From EuroPCR 2024
